Allogeneic stem cell therapy allows "off the shelf" cells to be used in therapy, rather than having to take cells from each individual patient, allowing a relatively fast and inexpensive therapy.
Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies ... and jointly develop T-cell therapy candidates against them.